IGF-I fusion polypeptides and therapeutic uses thereof
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsDavid J. Glass, George D. Yancopoulos, Thomas J. Daly, Nicholas J. Papadopoulos
Life of this patent
Estimating the term…
Abstract
A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibiting improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, a targeting ligand, or another active or therapeutic compound. IGF1 variants were shown to have improved ability to induce skeletal muscle hypertrophy relative to native IGF1.
Claims9
A fusion polypeptide, comprising:
- (a) an insulin-like growth factor 1 (IGF1) variant polypeptide component, comprising a human IGF1 protein of SEQ ID NO:1 with the deletions of amino acid residues 1-3, 37, and 65-70;
- and
- (b) a fusion component (F);
- wherein F is an Fc domain of human IgG, wherein the IGF1 variant polypeptide component retains the functional activity of IGF-1.
A method of producing the fusion polypeptide of claim 1, comprising culturing a host cell transfected with the vector of claim 9, under conditions suitable for expression of the polypeptide from the host cell, and recovering the polypeptide so produced.
Dependencies are inferred from the claim text.